Cathie Wood Still Interested In Psychedelics, She Bought Over 3 Million Atai Shares In July Alone

Several weeks ago, Cathie Wood's ARK Fund ARKG invested in the biotech psychedelics sector, specifically in major player Atai Life Sciences ATAI.  

The first purchase took place in February 2022, when ARK bought 83,278 shares of Atai Life Sciences. Less than two weeks later, the company acquired four times that, bringing its total ownership to over 340,000 shares, as first reported by Jason Najum on Microdose.

In early July 2022, the company’s spreadsheet showed it held a total 1,827,047 of Atai’s shares -representing an increase of more than 138,000 shares from March 2022. 

By mid-July, the total monthly investment was 621,812 shares. Yet ARK further acquired shares. Now it can be said that the total purchase of Atai stock for that month is over 3 million (3,018,751). 

Considering its rounding $4 for July, that’s $12 million invested in psychedelics by Cathie Wood’s fund, aka a noteworthy purchase from a celebrity investor

Photo Courtesy of Jeffrey Blum on Unsplash.

Posted In: BiotechCannabisNewsPenny StocksPsychedelicsSmall CapMarketsGeneralCathie WoodPsychedelics Investments


The Benzinga Cannabis Awards are coming back to the September 27-28, 2023 Cannabis Capital Conference to celebrate the NEWCREATIVE, INNOVATIVE, and OUTSTANDING companies of the cannabis industry.

  • Earn global recognition for your achievements.
  • Shine a spotlight on the people around you that deserve their moment.
  • Celebrate with the newest, hottest and most successful in the cannabis industry.

Nominate or apply NOW and help us celebrate the peoplesolutions, and companies leading the way in cannabis!

Join us on September 27-28, 2023 at Chicago Marriott Downtown Magnificent Mile in Chicago, IL.